

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/766,755		ATTY. DOCKET NO.: A0752.70001US01	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: January 28, 2004		CONFIRMATION NO.: 2264	
				APPLICANT: Gregory Stahl et al.			
				GROUP ART UNIT: 1644		EXAMINER: Francois P. Vandervegt	
Sheet	1	of	2				

U.S. PATENT DOCUMENTS

Examiner's Initials *	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		7,273,925		Stahl et al.	09-25-2007

FOREIGN PATENT DOCUMENTS

Examiner's Initials *	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] Alexion Pharmaceuticals: Product profiles: Myocardial infarction. http://www.alexionpharm.com/products/mi.cfm . Accessed November 8, 2000. 1 page.	
		[No Author Listed] Alexion Pharmaceuticals: Complement inhibitors. http://www.alexionpharm.com/techplat/complement.cfm . Accessed November 8, 2000. 2 pages.	
		[No Author Listed]. Alexion Pharmaceuticals and the Brigham and Women's Hospital form collaboration to develop novel anti-inflammatory antibody. Press release dated February 15, 2000. http://www.alexionpharm.com/news/sub_press.cfm?prid=159&selectyear=2000 . Accessed November 8, 2000. 2 pages.	
		[No Author Listed] Alexion Pharmaceuticals & Brigham and Women's Hospital scientists demonstrate new pathway for complement activation in cardiovascular disease. Press release dated May 3, 2000. http://www.alexionpharm.com/news/sub_press.cfm?prid=172&selectyear=2000 . Accessed November 8, 2000. 3 pages.	
		[No Author Listed] Scientific study published in Journal of Clinical Investigation demonstrates terminal complement activation causes kidney damage during ischemia and reperfusion. Press release dated May 15, 2000. http://www.alexionpharm.com/news/sub_press.cfm?prid=173&selectyear=2000 . Accessed November 8, 2000. 3 pages.	
		[No Author Listed] Read a story about complement in The Economist. Letter to shareholders and interested parties from Leonard Bell, MD, President and CEO of Alexion Pharmaceuticals, Inc. http://www.alexionpharm.com/news/sub_press.cfm?prid=174&selectyear=2000 . Accessed November 8, 2000. 2 pages.	
		JANEWAY et al., 3-19 (last paragraph) to 3-20. In Immunobiology. Garland Press. 2 pages.	
		JANEWAY et al., The distribution and functions of immunoglobulin isotypes. In Immunobiology. Garland Press. 3 pages.	
		JANEWAY et al., 13-11 (last 2 paragraphs) to 13-13 (first 4 lines of second paragraph). In Immunobiology. Garland Press. 3 pages.	
		JANEWAY et al., 13-6 (end of section) to 13-7 (first four paragraphs). In Immunobiology, Third Edition. Garland Press. 2 pages.	

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/766,755		ATTY. DOCKET NO.: A0752.70001US01	
				FILING DATE: January 28, 2004		CONFIRMATION NO.: 2264	
				APPLICANT: Gregory Stahl et al.			
				GROUP ART UNIT: 1644		EXAMINER: Francois P. Vandervegt	
Sheet	2	of	2				

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /Maher Haddad/	DATE CONSIDERED: 04/27/2010
--------------------------	-----------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.